CoChat
Sign Up
Cited by 1,079

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications - a review

Grygiel-Górniak, Bogna·2014·Nutrition Journal
DOI 10.1186/1475-2891-13-17PMC PMC3943808
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1475-2891-13-17

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 75

  1. Berger J, Moller DE: The mechanisms of action of PPARs. Annu Rev Med. 2002, 53: 409-435. 10.1146/annurev.med.53.082901.104018. · DOI · Paper page
  2. Boitier E, Gautier JC, Roberts R: Advances in understanding the regulation of apoptosis and mitosis by peroxisome-proliferator activated receptors in pre-clinical models: relevance for human health and disease. Comp Hepatol. 2003, 2 (1): 3-10.1186/1476-5926-2-3. · DOI
  3. Rogue A, Lambert C, Jossé R, Antherieu S, Spire C, Claude N, Guillouzo A: Comparative gene expression profiles induced by PPARγ and PPARα/γ agonists in human hepatocytes. PLoS One. 2011, 6 (4): e18816-10.1371/journal.pone.0018816. · DOI
  4. Rogue A, Spire C, Brun M, Claude N, Guillouzo A: Gene expression changes induced by PPAR gamma agonists in animal and human liver. PPAR Res. 2010, 2010: 325183- · DOI
  5. Willson TM, Brown PJ, Sternbach DD, Henke BR: The PPARs: from orphan receptors to drug discovery. J Med Chem. 2000, 43: 527-550. 10.1021/jm990554g. · DOI · Paper page
  6. Viswakarma N, Jia Y, Bai L, Vluggens A, Borensztajn J, Xu J, Reddy JK: Coactivators in PPAR-regulated gene expression. PPAR Res. 2010, 2010: 2050126- · DOI
  7. Heikkinen S, Auwerx J, Argmann CA: PPARγ in human and mouse physiology. Biochim Biophys Acta. 2007, 1771 (8): 999-1013. 10.1016/j.bbalip.2007.03.006. · DOI
  8. Ren D, Collingwood TN, Rebar EJ, Wolffe AP, Camp HS: PPARgamma knockdown by engineered transcription factors: exogenous PPARgamma2 but not PPARgamma1 reactivates adipogenesis. Genes Dev. 2002, 16 (1): 27-32. 10.1101/gad.953802. · DOI
  9. Werman A, Hollenberg A, Solanes G, Bjorbaek C, Vidal-Puig AJ, Flier JS: Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and -2 isoforms and influence of insulin. J Biol Chem. 1997, 272 (32): 20230-20235. 10.1074/jbc.272.32.20230. · DOI
  10. Sertznig P, Seifert M, Tilgen W, Reichrath J: Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer. J Cell Physiol. 2007, 212 (1): 1-12. 10.1002/jcp.20998. · DOI
  11. Neschen S, Morino K, Dong J, Wang-Fischer Y, Cline GW, Romanelli AJ, Rossbacher JC, Moore IK, Regittnig W, Munoz DS, Kim JH, Shulman GI: n-3 Fatty acids preserve insulin sensitivity in vivo in a peroxisome proliferator-activated receptor-alpha-dependent manner. Diabetes. 2007, 56 (4): 1034-1041. 10.2337/db06-1206. · DOI
  12. Delerive P, Furman C, Teissier E, Fruchart J, Duriez P, Staels B: Oxidized phospholipids activate PPARalpha in a phospholipase A2-dependent manner. FEBS Lett. 2000, 471 (1): 34-38. 10.1016/S0014-5793(00)01364-8. · DOI
  13. Lo Verme J, Fu J, Astarita G, La Rana G, Russo R, Calignano A, Piomelli D: The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol Pharmacol. 2005, 67 (1): 15-19. 10.1124/mol.104.006353. · DOI · Paper page
  14. Sheu SH, Kaya T, Waxman DJ, Vajda S: Exploring the binding site structure of the PPAR gamma ligand-binding domain by computational solvent mapping. Biochemistry (Mosc). 2005, 44 (4): 1193-1209. 10.1021/bi048032c. · DOI
  15. Lehrke M, Lazar MA: The many faces of PPARgamma. Cell. 2005, 123 (6): 993-999. 10.1016/j.cell.2005.11.026. · DOI
  16. Medina-Gomez G, Gray SL, Yetukuri L, Shimomura K, Virtue S, Campbell M, Curtis RK, Jimenez-Linan M, Blount M, Yeo GSH, Lopez M, Seppänen-Laakso T, Ashcroft FM, Orešič M, Vidal-Puig A: PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. PLoS Genet. 2007, 3 (4): e64-10.1371/journal.pgen.0030064. · DOI
  17. Stephen RL, Gustafsson MC, Jarvis M, Tatoud R, Marshall BR, Knight D, Ehrenborg E, Harris AL, Wolf CR, Palmer CN: Activation of peroxisome proliferator-activated receptor delta stimulates the proliferation of human breast and prostate cancer cell lines. Cancer Res. 2004, 64 (9): 3162-3170. 10.1158/0008-5472.CAN-03-2760. · DOI
  18. Rao MS, Kashireddy P, Musunuri S, Okonkwo A: Prevention/reversal of choline deficiency-induced steatohepatitis by a peroxisomeproliferator-activated receptor alpha ligand in rats. In Vivo. 2002, 16 (2): 145-152.
  19. Krey G, Braissant O, L'Horset F, Kalkhoven E, Perroud M, Parker MG, Wahli W: Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol. 1997, 11 (6): 779-791. 10.1210/mend.11.6.0007. · DOI
  20. Margeli A, Kouraklis G, Theocharis S: Peroxisome proliferator activated receptor-gamma (PPAR-gamma) ligands and angiogenesis. Angiogenesis. 2003, 6 (3): 165-169. · DOI
  21. Plutzky J: Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigms. Curr Atheroscler Rep. 2000, 2 (4): 327-335. 10.1007/s11883-000-0067-3. · DOI
  22. Bang JO, Dyberg J: Fish oil consumption and mortality from coronary heart disease. N Engl J Med. 1985, 313: 822-823.
  23. Taniguchi A, Fukushima M, Sakai M, Tokuyama K, Nagata I, Fukunaga A, Kishimoto H, Doi K, Yamashita Y, Matsuura T, Kitatani N, Okumura T, Nagasaka S, Nakaishi S, Nakai Y: Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients. Metabolism. 2001, 50 (4): 477-480. 10.1053/meta.2001.21028. · DOI
  24. Bakris GL, Dole JF, Porter LE, Huang C, Freed MI: Rosiglitazone improves blood pressure in patients with type 2 diabetes mellitus. Diabetes. 2000, 49 (suppl 1): A96-
  25. Nakamura T, Ushiyama C, Shimada N, Hayashi K, Ebihara I, Koide H: Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. J Diabetes Complications. 2000, 14 (5): 250-254. 10.1016/S1056-8727(00)00124-0. · DOI
  26. Fruchart JC, Staels B, Duriez P: The role of fibric acids in atherosclerosis. Curr Atheroscler Rep. 2001, 3 (1): 83-92. 10.1007/s11883-001-0015-x. · DOI
  27. Volker D, Fitzgerald P, Major G, Garg M: Efficacy of fish oil concentrate in the treatment of rheumatoid arthritis. J Rheumatol. 2000, 27 (10): 2343-2346.
  28. Sethi S, Ziouzenkova O, Ni H, Wagner DD, Plutzky J, Mayadas TN: Oxidized omega-3 fatty acids in fish oil inhibit leukocyte-endothelial interactions through activation of PPAR alfa. Blood. 2002, 100 (4): 1340-1346. 10.1182/blood-2002-01-0316. · DOI
  29. Rao MS, Reddy JK: PPAR alpha in the pathogenesis of fatty liver disease. Hepatology. 2004, 40 (4): 783-786. 10.1002/hep.20453. · DOI
  30. Schwimmer JB, Behling C, Newbury R, Deutsch R, Nievergelt C, Schork NJ, Lavine JE: Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology. 2005, 42 (3): 641-649. 10.1002/hep.20842. · DOI
  31. Ip E, Farrell GC, Robertson G, Hall P, Kirsch R, Leclercq I: Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology. 2003, 38 (1): 123-132. 10.1053/jhep.2003.50307. · DOI · Paper page
  32. Kris-Etherton PM, Harris WS, Appel LJ: Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002, 106 (21): 2747-2757. 10.1161/01.CIR.0000038493.65177.94. · DOI · Paper page
  33. Diabetes Atherosclerosis Intervention Study Investigators: Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001, 357 (9260): 905-910. · DOI
  34. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d’Emden M, Whiting M, Ehnholm C, Laakso M, FIELD study investigators: Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005, 366 (9500): 1849-1861. · DOI · Paper page
  35. Hottelart C, El Esper N, Rose F, Achard JM, Fournier A: Fenofibrate increases creatininemia by increasing metabolic production of creatinine. Nephron. 2002, 92 (3): 536-541. 10.1159/000064083. · DOI · Paper page
  36. Berger J, Leibowitz MD, Doebber TW, Elbrecht A, Zhang B, Zhou G, Biswas C, Cullinan CA, Hayes NS, Li Y, Tanen M, Ventre J, Wu MS, Berger GD, Mosley R, Marquis R, Santini C, Sahoo SP, Tolman RL, Smith RG, Moller DE: Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J Biol Chem. 1999, 274 (10): 6718-6725. 10.1074/jbc.274.10.6718. · DOI
  37. Ngala RA, Stocker CJ, Roy AG, Hislop D, Wargent E, Bell R, Hassall DG, Harling JD, Billin AN, Willson TM, Arch JR, Cawthorne MA: A new, highly selective marine peroxisome proliferator-activated receptor delta agonist increases responsiveness to thermogenic stimuli and glucose uptake in skeletal muscle in obese mice. Diab Obes Metab. 2011, 13 (5): 455-464. 10.1111/j.1463-1326.2011.01371.x. · DOI
  38. Burkart EM, Sambandam N, Han X, Gross RW, Courtois M, Gierasch CM, Shoghi K, Welch MJ, Kelly DP: Nuclear receptors PPAR beta/delta and PPAR alpha direct distinct metabolic regulatory programs in the mouse heart. J Clin Invest. 2007, 117 (12): 3930-3939.
  39. Yu BC, Chang CK, Ou HY, Cheng KC, Cheng JT: Decrease of peroxisome proliferator-activated receptor delta expression in cardiomyopathy of streptozotocin-induced diabetic rats. Cardiovasc Res. 2008, 80 (1): 78-87. 10.1093/cvr/cvn172. · DOI
  40. Lim H, Dey SK: PPAR delta functions as a prostacyclin receptor in blastocyst implantation. Trends Endocrinol Metab. 2000, 11 (4): 137-142. 10.1016/S1043-2760(00)00243-5. · DOI
  41. Michalik L, Desvergne B, Wahli W: Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer. 2004, 4 (1): 61-70. 10.1038/nrc1254. · DOI
  42. Henke BR: Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes. J Med Chem. 2004, 47 (17): 4118-4127. 10.1021/jm030631e. · DOI
  43. Kintscher U, Law RE: PPARγmediated insulin sensitization: the importance of fat versus muscle. Am J Physiol Endocrinol Metab. 2005, 288 (2): E287-E291. 10.1152/ajpendo.00440.2004. · DOI
  44. Marx N, Bourcier T, Sukhova GK, Libby P, Plutzky J: PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Arterioscler Thromb Vasc Biol. 1999, 19 (3): 546-551. 10.1161/01.ATV.19.3.546. · DOI
  45. Sporn MB, Suh N, Mangelsdorf DJ: Prospects for prevention and treatment of cancer with selective PPARγ modulators (SPARMs). Trends Mol Med. 2001, 7 (9): 395-400. 10.1016/S1471-4914(01)02100-1. · DOI
  46. Trombetta A, Maggiora M, Martinasso G, Cotogni P, Canuto RA, Muzio G: Arachidonic and docosahexaenoic acids reduce the growth of A549 human lung-tumor cells increasing lipid peroxidation and PPARs. Chem Biol Interact. 2007, 165 (3): 239-250. 10.1016/j.cbi.2006.12.014. · DOI
  47. Edwards IJ, Berquin IM, Sun H, O'Flaherty JT, Daniel LW, Thomas MJ, Rudel LL, Wykle RL, Chen YQ: Differential effects of delivery of omega-3 fatty acids to human cancer cells by low-density lipoproteins versus albumin. Clin Cancer Res. 2004, 10 (24): 8275-8283. 10.1158/1078-0432.CCR-04-1357. · DOI
  48. Sun H, Berquin IM, Edwards IJ: Omega-3 polyunsaturated fatty acids regulate syndecan-1 expression in human breast cancer cells. Cancer Res. 2005, 65 (10): 4442-4447. 10.1158/0008-5472.CAN-04-4200. · DOI
  49. Sun H, Berquin IM, Owens RT, O'Flaherty JT, Edwards IJ: Peroxisome proliferator-activated receptor γ-mediated up-regulation of syndecan-1 by n-3 fatty acids promotes apoptosis of human breast cancer cells. Cancer Res. 2008, 68 (8): 2912-2919. 10.1158/0008-5472.CAN-07-2305. · DOI
  50. Yang ZH, Miyahara H, Iwasaki Y, Takeo J, Katayama M: Dietary supplementation with long-chain monounsaturated fatty acids attenuates obesity-related metabolic dysfunction and increases expression of PPAR gamma in adipose tissue in type 2 diabetic KK-Ay mice. Nutr Metab (Lond). 2013, 10 (1): 16-10.1186/1743-7075-10-16. · DOI
  51. Mishra A, Chaudhary A, Sethi S: Oxidized omega-3 fatty acids inhibit NF-κB activation via a PPARα-dependent pathway. Arterioscler Thromb Vasc Biol. 2004, 24 (9): 1621-1627. 10.1161/01.ATV.0000137191.02577.86. · DOI
  52. Suchanek KM, May FJ, Robinson JA, Lee WJ, Holman NA, Monteith GR, Roberts-Thomson SJ: Peroxisome proliferator-activated receptor alpha in the human breast cancer cell lines MCF-7 and MDA-MB-231. Mol Carcinog. 2002, 34 (4): 165-171. 10.1002/mc.10061. · DOI
  53. Heim M, Johnson J, Boess F, Bendik I, Weber P, Hunziker W, Fluhmann B: Phytanic acid, a natural peroxisome proliferator-activated receptor (PPAR) agonist, regulates glucose metabolism in rat primary hepatocytes. FASEB J. 2002, 16 (7): 718-720. · DOI
  54. Elstner E, Mu¨ller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D, Koeffler HP: Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A. 1998, 95 (15): 8806-8811. 10.1073/pnas.95.15.8806. · DOI
  55. Tan MH: Current treatment of insulin resistance in type 2 diabetes mellitus. Int J Clin Pract Suppl. 2000, 113: 54-62.
  56. Deeg MA, Tan MH: Pioglitazone versus rosiglitazone: effects on lipids, lipoproteins, and apolipoproteins in head-to-head randomized clinical studies. PPAR Res. 2008, 2008: 520465- · DOI
  57. Krishnaswami A, Ravi-Kumar S, Lewis JM: Thiazolidinediones: a 2010 perspective. Perm J. 2010, 14 (3): 64-72. · DOI
  58. Chang F, Jaber LA, Berlie HD, O’Connell MB: Evolution of peroxisome proliferator-activated receptor agonists. Ann Pharmacother. 2007, 41 (6): 973-983. 10.1345/aph.1K013. · DOI
  59. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL: Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care. 2000, 23 (11): 1605-1611. 10.2337/diacare.23.11.1605. · DOI
  60. Raskin P, Rappaport EB, Cole ST, Yan Y, Patwardhan R, Freed MI: Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia. 2000, 43 (3): 278-284. 10.1007/s001250050045. · DOI
  61. Dormandy J, Bhattacharya M, Van Troostenburg de Bruyn AR: Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf. 2009, 32 (3): 187-202. 10.2165/00002018-200932030-00002. · DOI
  62. Peters Harmel AL, Kendall DM, Buse JB, Boyle PJ, Marchetti A, Lau H: Impact of adjunctive thiazolidinedione therapy on blood lipid levels and glycemic control in patients with type 2 diabetes. Curr Med Res Opin. 2004, 20 (2): 215-223. 10.1185/030079903125002937. · DOI
  63. Diamant M, Heine RJ: Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs. 2003, 63 (13): 1373-1405. 10.2165/00003495-200363130-00004. · DOI
  64. Caballero A, Saouaf R, Lim SC, Hamdy O, Abou-Elenin K, O’Connor C, LoGerfo FW, Horton ES, Veves A: The effects of troglitazone, an insulin-sensitizing agent, on the endothelial function in early and late type 2 diabetes: a placebo-controlled randomized clinical trial. Metabolism. 2003, 52 (2): 173-180. 10.1053/meta.2003.50023. · DOI
  65. Bagi Z, Koller A, Kaley G: PPARgamma activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes. Am J Physiol Heart Circ Physiol. 2004, 286 (2): H742-H748. 10.1152/ajpheart.00718.2003. · DOI
  66. Marlow LA, Reynolds LA, Cleland AS, Cooper SJ, Gumz ML, Kurakata S, Fujiwara K, Zhang Y, Sebo T, Grant C, McIver B, Wadsworth JT, Radisky DC, Smallridge RC, Copland JA: Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth. Cancer Res. 2009, 69 (4): 1536-1544. 10.1158/0008-5472.CAN-08-3718. · DOI
  67. Tolman KG: The safety of thiazolidinediones. Expert Opin Drug Saf. 2011, 10 (3): 419-428. 10.1517/14740338.2011.534982. · DOI
  68. Rubenstrunk A, Hanf R, Hum DW, Fruchart JC, Staels B: Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta. 2007, 1771 (8): 1065-1081. 10.1016/j.bbalip.2007.02.003. · DOI · Paper page
  69. Carmona MC, Louche K, Lefebvre B, Pilon A, Hennuyer N, Audinot-Bouchez V, Fievet C, Torpier G, Formstecher P, Renard P, Lefebvre P, Dacquet C, Staels B, Casteilla L, Pénicaud L, Consortium of the French Ministry of Research and Technology: S 26948: a new specific peroxisome proliferator activated receptor gamma modulator with potent antidiabetes and antiatherogenic effects. Diabetes. 2007, 56 (11): 2797-2808. 10.2337/db06-1734. · DOI
  70. Dunn FL, Higgins LS, Fredrickson J, DePaoli AM: Selective modulation of PPARgamma activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes. J Diabetes Complicat. 2011, 25 (3): 151-158. 10.1016/j.jdiacomp.2010.06.006. · DOI
  71. Grommes C, Landreth GE, Heneka MT: Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol. 2004, 5 (7): 419-429. 10.1016/S1470-2045(04)01509-8. · DOI
  72. Long GG, Reynolds VL, Lopez-Martinez A, Ryan TE, White SL, Eldridge SR: Urothelial carcinogenesis in the urinary bladder of rats treated with naveglitazar, a gamma-dominant PPAR alpha/gamma agonist: lack of evidence for urolithiasis as an inciting event. Toxicol Pathol. 2008, 36 (2): 218-231. 10.1177/0192623307311757. · DOI
  73. Wilding JP, Gause-Nilsson I, Persson A: Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes. Diab Vasc Dis Res. 2007, 4 (3): 194-203. · DOI
  74. Nissen SE, Wolski K, Topol EJ: Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2005, 294 (20): 2581-2586. 10.1001/jama.294.20.joc50147. · DOI
  75. Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M: Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet. 2009, 374 (9684): 126-135. 10.1016/S0140-6736(09)60870-9. · DOI

Cited by

Sorted by citations

Metadata

Authors
Grygiel-Górniak, B.
Venue
Nutrition Journal
Publisher
Springer Science and Business Media LLC
Published
2014-02-14
Volume
13
Issue
1
ISSN
1475-2891
DOI
10.1186/1475-2891-13-17
PMC
PMC3943808
Cited by
1,079
References
8
Language
en
Licence
www.springer.com/tdm (unspecified)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review